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low. Endovascular repair of symptomatic, ruptured and
large PAU is safe and effective with excellent long-term
results. For asymptomatic PAU, serial CT surveillance is
associated with a low rate of rupture or complications.
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Objectives: It is unclear whether the type of proximal
ﬁxation and radial force associated with EVAR have any
long-term impact on the aneurysm neck diameter
(AND). We sought to identify whether AND changes
occur and if any factors are associated with changes in
AND.
Methods: Post-EVAR computed tomography images
were reviewed for all patients undergoing EVAR at two
tertiary medical centers between November 2002 and
March 2012 for whom >6 month post-EVAR imaging
was obtained. The AND was deﬁned as the minor axis 1
cm inferior to the lowest renal artery. AND changes were
calculated as the difference between pre-EVAR AND and
AND at last follow-up scan. EVAR stent-graft type and
other patient characteristics were obtained from chart
review. Multivariable linear regression was used to identify
factors independently associated with long-term AND
changes.
Results: A total of 151 patients meeting inclusion
criteria underwent EVAR with one of ﬁve stent-graft
types. The median age was 70 years old, and median
follow-up time for these patients was 2.05 years. The
mean initial AND was 24.5 mm, and the median AND
change was -0.2 mm/yr. AND expansion >1 mm/yr
occurred in 27 patients (17.8%). Multivariable regression
demonstrated that larger initial AND (P ¼ .001) and dia-
betes mellitus (P ¼ .03) were associated with reduced
risk of AND expansion. The Zenith (P < .001) and
the Talent (P ¼ .07) stent-grafts were associated with
increased risk of AND expansion compared to Excluder,
Aneurx, and Powerlink devices. Overall, stent-grafts with
suprarenal ﬁxation were associated with increased rate of
AND expansion compared to those that did not have
suprarenal ﬁxation (P ¼ .01).
Conclusions: Signiﬁcant AND expansion after
EVAR is uncommon. Necks that do expand only do
so marginally but suprarenal ﬁxation appears to beassociated with an increased risk of long-term AND
expansion. Future studies should address the incidence
of AND during longer follow up and the relationship
between AND expansion and secondary interventions
after EVAR.
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Safety of Percutaneous TEVAR in Obese Patients
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Objectives: There are limited data describing the
“Preclose” technique in TEVAR (P-TEVAR), particularly
in obese patients (BMI $ 30kg/m2), in whom this tech-
nique is thought to be contraindicated. We describe our
experience with P-TEVAR and compare outcomes in
obese and nonobese patients.
Methods: All patients undergoing TEVAR at a single
institution from ’05-11 were reviewed; patients under-
going P-TEVAR were identiﬁed and stratiﬁed by BMI.
Technical success was deﬁned as the ability to achieve
hemostasis and maintain limb perfusion without the need
for surgical repair of the vessel.
Results: Of 536 TEVARs, 359 (67%) P-TEVAR
procedures were completed. For the entire P-TEVAR
cohort, mean age 6 SD was 62.9 6 15.7 yrs with BMI
of 27.56 5.4. Mean sheath diameter, largest TEVAR stent
diameter, and number of Perclose deployments were 22.4
6 2.5F, 34.6 6 7.8 mm and 2.1 6 0.4, respectively. Mean
access vessel inner diameter was 8.0 6 2.0 mm with
average depth of 35.6 6 17.5 mm. Adjunctive iliac stents
were used in 9.4% (n ¼ 34). Overall “Preclose” success
rate was 92.6%:92.2% for nonobese patients and 93.8%
for obese patients (P ¼ .57). 3 patients required subse-
quent operations for access complications: two obese
patients (2%) and one nonobese patient (0.3%). By univar-
iate analysis, higher age, increased sheath size, larger aortic
stent diameter, use of more than 2 Perclose devices, need
for iliac stents, and higher femoral artery calcium score
were associated with failure. Independent predictors of
failure were adjunctive iliac stent (OR, 8.9; 95% CI, 2.9-
27.4; P ¼ .003), >2 Perclose devices (OR, 6.7; 95% CI,
2.2-20.2; P ¼ .001), and decreased access vessel diameter
(OR, 1.5; 95% CI, 1.1-2; P ¼ .008).
Conclusions: Percutaneous endovascular repair of
thoracic aortic pathology is safe. Obesity does not appear
to be a contraindication for the “Preclose” technique.
Patients predicted to need adjunctive stenting or possessing
smaller access vessel diameters with greater degree of calci-
ﬁcation are at highest risk of failure and selective use of this
technique is recommended.
